Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated:  9/23/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated: 9/23/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated:  9/23/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated: 9/23/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated:  9/23/2013
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated: 9/23/2013
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated:  9/23/2013
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated: 9/23/2013
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated:  9/23/2013
M D Anderson Cancer Center
mi
from
Houston, TX
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated: 9/23/2013
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated:  9/24/2013
Clinical Research Facility
mi
from
Alexandria, LA
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated: 9/24/2013
Clinical Research Facility
mi
from
Alexandria, LA
Click here to add this to my saved trials
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated:  9/24/2013
Clinical Research Facility
mi
from
Albuquerque, NM
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated: 9/24/2013
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated:  9/24/2013
Clinical Research Facility
mi
from
Dallas, TX
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated: 9/24/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated:  9/24/2013
Clinical Research Facility
mi
from
Houston, TX
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated: 9/24/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Chemotherapy Resistance and Sensitivity Testing in Lung Tumors
Chemotherapy Resistance and Sensitivity Testing in Lung Tumors
Status: Enrolling
Updated:  9/24/2013
Cabell Huntington Hospital
mi
from
Huntington, WV
Chemotherapy Resistance and Sensitivity Testing in Lung Tumors
Chemotherapy Resistance and Sensitivity Testing in Lung Tumors
Status: Enrolling
Updated: 9/24/2013
Cabell Huntington Hospital
mi
from
Huntington, WV
Click here to add this to my saved trials
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  9/25/2013
Clinical Research Facility
mi
from
Aurora, CO
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 9/25/2013
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  9/25/2013
Clinical Research Facility
mi
from
Indianapolis, IN
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 9/25/2013
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  9/25/2013
Clinical Research Facility
mi
from
Boston, MA
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 9/25/2013
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  9/25/2013
Clinical Research Facility
mi
from
Detroit, MI
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 9/25/2013
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  9/25/2013
Clinical Research Facility
mi
from
St. Louis, MO
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 9/25/2013
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  9/25/2013
Clinical Research Facility
mi
from
New York, NY
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 9/25/2013
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  9/25/2013
Clinical Research Facility
mi
from
Columbus, OH
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 9/25/2013
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  9/25/2013
Clinical Research Facility
mi
from
Oklahoma City, OK
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 9/25/2013
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms
Status: Enrolling
Updated:  9/30/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms
Status: Enrolling
Updated: 9/30/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma
The Role of Gadoxetate Enhanced Spectral Dual-Energy CT in Evaluating Hilar Cholangiocarcinoma
Status: Enrolling
Updated:  9/30/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma
The Role of Gadoxetate Enhanced Spectral Dual-Energy CT in Evaluating Hilar Cholangiocarcinoma
Status: Enrolling
Updated: 9/30/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  9/30/2013
Stanford University Cancer Institute
mi
from
Stanford, CA
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 9/30/2013
Stanford University Cancer Institute
mi
from
Stanford, CA
Click here to add this to my saved trials
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  9/30/2013
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 9/30/2013
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Click here to add this to my saved trials
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  9/30/2013
Karmanos Cancer Institute / Wayne State University
mi
from
Detroit, MI
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 9/30/2013
Karmanos Cancer Institute / Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  9/30/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 9/30/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  9/30/2013
UNC Lineberger Comprehensive Cancer Center / University of North Carolina
mi
from
Chapel Hill, NC
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 9/30/2013
UNC Lineberger Comprehensive Cancer Center / University of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  9/30/2013
Miriam Hospital, The
mi
from
Providence, RI
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 9/30/2013
Miriam Hospital, The
mi
from
Providence, RI
Click here to add this to my saved trials
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  9/30/2013
Sarah Cannon Research Institute
mi
from
Nashville, TN
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 9/30/2013
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  9/30/2013
Seattle Cancer Care Alliance / University of Washington
mi
from
Seattle, WA
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 9/30/2013
Seattle Cancer Care Alliance / University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in CRC Screening
A Randomized, Controlled Trial Comparing Air Insufflation, Water Immersion and Water Exchange During on Demand Sedation Colonoscopy in CRC Screening Patients
Status: Enrolling
Updated:  9/30/2013
Sepulveda Ambulatory Care Center, VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in CRC Screening
A Randomized, Controlled Trial Comparing Air Insufflation, Water Immersion and Water Exchange During on Demand Sedation Colonoscopy in CRC Screening Patients
Status: Enrolling
Updated: 9/30/2013
Sepulveda Ambulatory Care Center, VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated:  9/30/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated: 9/30/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated:  9/30/2013
Weill Cornell Breast Center
mi
from
New York, NY
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated: 9/30/2013
Weill Cornell Breast Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated:  9/30/2013
Beth Israel Medical Center, Comprehensive Cancer Center
mi
from
New York, NY
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated: 9/30/2013
Beth Israel Medical Center, Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated:  9/30/2013
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated: 9/30/2013
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors
Status: Enrolling
Updated:  9/30/2013
Clinical Research Facility
mi
from
Tampa, FL
Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors
Status: Enrolling
Updated: 9/30/2013
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors
Status: Enrolling
Updated:  9/30/2013
Clinical Research Facility
mi
from
Oklahoma City, OK
Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors
Status: Enrolling
Updated: 9/30/2013
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors
Status: Enrolling
Updated:  9/30/2013
Clinical Research Facility
mi
from
San Antonio, TX
Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors
Status: Enrolling
Updated: 9/30/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
Status: Enrolling
Updated:  10/10/2013
Stanford University School of Medicine
mi
from
Stanford, CA
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
Status: Enrolling
Updated: 10/10/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study
THE EFFECTS OF YOGA ON QUALITY OF LIFE AMONG A POPULATION OF OVARIAN/ FALLOPIAN TUBE/ PRIMARY PERITONEAL CANCER PATIENTS RECEIVING CHEMOTHERAPY: A FEASIBILITY STUDY
Status: Enrolling
Updated:  10/10/2013
Northwestern Memorial Hospital
mi
from
Chicago, IL
The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study
THE EFFECTS OF YOGA ON QUALITY OF LIFE AMONG A POPULATION OF OVARIAN/ FALLOPIAN TUBE/ PRIMARY PERITONEAL CANCER PATIENTS RECEIVING CHEMOTHERAPY: A FEASIBILITY STUDY
Status: Enrolling
Updated: 10/10/2013
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study
Pilot Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study
Status: Enrolling
Updated:  10/11/2013
Stanford University Cancer Institute
mi
from
Stanford, CA
Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study
Pilot Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study
Status: Enrolling
Updated: 10/11/2013
Stanford University Cancer Institute
mi
from
Stanford, CA
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Mayo Clinic, AZ
mi
from
Scottsdale, AZ
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Mayo Clinic, AZ
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Genesis Cancer Center
mi
from
Hot Springs, AR
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Genesis Cancer Center
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Northeast Arkansas Clinic
mi
from
Jonesboro, AR
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Northeast Arkansas Clinic
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Wilshire Oncology Medical Group
mi
from
LaVerne, CA
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Wilshire Oncology Medical Group
mi
from
LaVerne, CA
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Aventura Medical Center
mi
from
Aventura, FL
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Aventura Medical Center
mi
from
Aventura, FL
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Collaborative Research Group/ Palm Beach Ins of Hem Onc
mi
from
Boynton Beach, FL
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Collaborative Research Group/ Palm Beach Ins of Hem Onc
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Florida Cancer Specialists
mi
from
Fort Myers, FL
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Holy Cross Hospital
mi
from
Ft. Lauderdale, FL
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Holy Cross Hospital
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Memorial Regional Cancer Center
mi
from
Hollywood, FL
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Memorial Regional Cancer Center
mi
from
Hollywood, FL
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Watson Clinic Center for Cancer Care and Research
mi
from
Lakeland, FL
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Watson Clinic Center for Cancer Care and Research
mi
from
Lakeland, FL
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Mount Sinai Comprehensive Cancer Center
mi
from
Miami Beach, FL
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Mount Sinai Comprehensive Cancer Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials